Dan Hu1, Zhaolei Cui2, Wei Peng3, Xiaojiang Wang4, Yapeng Chen5, Xiufeng Wu6. 1. Fujian Cancer Hospital, Department of Pathology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, People's Republic of China. 2. Fujian Cancer Hospital, Laboratory of Biochemistry and Molecular Biology Research, Department of Clinical Laboratory, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, People's Republic of China. 3. Fujian Cancer Hospital, Department of Clinical Laboratory, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, People's Republic of China. 4. Fujian Cancer Hospital, Department of Molecular Pathology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, People's Republic of China. 5. Fujian Cancer Hospital, Clinical Department of Fujian Medical University, Fuzhou, 350000, Fujian, People's Republic of China. 6. Fujian Cancer Hospital, Department of Breast Surgical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, People's Republic of China. wxf200104@hotmail.com.
Abstract
PURPOSE: Apelin has been shown to be a novel angiogenic factor in various cancers. However, there is limited information regarding the role of apelin in breast cancer. The aim of the present study is to examine associations between apelin, clinicopathological variables, and clinical outcome in breast cancer patients. METHODS: In this study, we began by investigating the apelin expression in breast cancer with long-term follow-up using immunohistochemistry. We then analyzed the relationship between apelin expression and microvessel density (MVD), lymphatic vessel density (LVD), lymph node status as well as other established clinicopathological parameters. The relationship between apelin expression and prognosis was also studied. In addition, we compared the apelin and its ligant APJ expression between 30 breast cancer samples and normal breast tissues adjacent to the breast tumors using western blot (WB) and RT-PCR. RESULTS: Apelin protein expression was detected in the cytoplasm of the breast carcinoma cells at various intensities. Apelin expression was positive in 59.2% (84/142) of the breast cancer patients and apelin expression was significantly correlated with tumor size (p = 0.030), stage (p = 0.000), histological type (p = 0.009), MVD (p = 0.000), LVD (p = 0.000), and lymph node metastasis (p = 0.041). Survival curves determined by the Kaplan-Meier method and univariate analysis demonstrated that high expression of apelin was associated with both worse disease-free survival (p < 0.001) and overall survival (p < 0.001). Interestingly, a significant difference in apelin and APJ expression by WB as well as RT-PCR was observed between normal breast tissues adjacent to the breast tumors and breast cancer tissues. CONCLUSIONS: Our results showed apelin expression was associated with tumor size, stage, histological type, MVD, LVD, lymph node metastasis and poor prognosis. The presence of apelin may be a new prognostic factor and potential therapeutic target for breast cancer.
PURPOSE: Apelin has been shown to be a novel angiogenic factor in various cancers. However, there is limited information regarding the role of apelin in breast cancer. The aim of the present study is to examine associations between apelin, clinicopathological variables, and clinical outcome in breast cancer patients. METHODS: In this study, we began by investigating the apelin expression in breast cancer with long-term follow-up using immunohistochemistry. We then analyzed the relationship between apelin expression and microvessel density (MVD), lymphatic vessel density (LVD), lymph node status as well as other established clinicopathological parameters. The relationship between apelin expression and prognosis was also studied. In addition, we compared the apelin and its ligant APJ expression between 30 breast cancer samples and normal breast tissues adjacent to the breast tumors using western blot (WB) and RT-PCR. RESULTS: Apelin protein expression was detected in the cytoplasm of the breast carcinoma cells at various intensities. Apelin expression was positive in 59.2% (84/142) of the breast cancer patients and apelin expression was significantly correlated with tumor size (p = 0.030), stage (p = 0.000), histological type (p = 0.009), MVD (p = 0.000), LVD (p = 0.000), and lymph node metastasis (p = 0.041). Survival curves determined by the Kaplan-Meier method and univariate analysis demonstrated that high expression of apelin was associated with both worse disease-free survival (p < 0.001) and overall survival (p < 0.001). Interestingly, a significant difference in apelin and APJ expression by WB as well as RT-PCR was observed between normal breast tissues adjacent to the breast tumors and breast cancer tissues. CONCLUSIONS: Our results showed apelin expression was associated with tumor size, stage, histological type, MVD, LVD, lymph node metastasis and poor prognosis. The presence of apelin may be a new prognostic factor and potential therapeutic target for breast cancer.